Phase 4 study evaluates nitroglycerin's effects on stroke volume in 21 AHF patients

A Phase 4 study, completed at Copenhagen University Hospital, Hvidovre, evaluated the effects of nitroglycerin on heart function and urinary output in patients with acute heart failure (AHF). The study aimed to understand how nitroglycerin, which relaxes blood vessels, affects patients with AHF, a condition characterized by the heart struggling to pump blood effectively, leading to fluid buildup and breathing difficulties. The investigators hypothesized that nitroglycerin could increase blood flow from the heart and promote urine production, potentially reducing congestion in AHF patients. The primary outcome measured was stroke volume. The study enrolled 21 patients with AHF. The study period ran from February 1, 2025, to November 30, 2025. The goal of the research was to identify which patients may benefit most from nitroglycerin therapy by studying heart function, blood volume, and fluid levels during treatment. The abstract does not report specific results, safety signals, or study limitations.

Imagine your heart suddenly struggling to pump blood. Fluid backs up into your lungs, making every breath a fight. That's acute heart failure. Doctors often use a drug called nitroglycerin in these emergencies. It works by relaxing and widening blood vessels, which takes some pressure off the tired heart. This study wanted to understand exactly how that drug helps in the crucial early hours of treatment. The researchers had a specific idea: that nitroglycerin would do two key things. First, increase the amount of blood the heart pumps out with each beat (called stroke volume). Second, help the kidneys make more urine, which is the body's way of flushing out the dangerous extra fluid causing congestion and shortness of breath. By closely watching 21 patients, the team measured heart function, blood volume, and fluid levels during nitroglycerin treatment. Their main goal wasn't just to see if the drug worked, but to identify the specific types of patients who respond best to it. This knowledge could help doctors use this common medication more precisely, targeting it to the people most likely to get rapid relief from that terrifying feeling of drowning in their own fluid.